METHODS AND COMPOSITIONS FOR TREATING CANCER
The invention provides methods and compositions for use in treating cancer, e.g., gastric cancer (e.g., a gastric carcinoma (GC) or a gastroesophageal junction carcinoma (GEJC) (e.g., inoperable, locally advanced, metastatic, or advanced GC or GEJC)) or rectal cancer (e.g., locally advanced rectal c...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English |
Published |
27.06.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention provides methods and compositions for use in treating cancer, e.g., gastric cancer (e.g., a gastric carcinoma (GC) or a gastroesophageal junction carcinoma (GEJC) (e.g., inoperable, locally advanced, metastatic, or advanced GC or GEJC)) or rectal cancer (e.g., locally advanced rectal cancer (LARC)) in a subject, for example, by administering to the subject a treatment regimen that includes an anti-TIGIT antagonist antibody (e.g., tiragolumab) in combination with a PD-1 axis binding antagonist (e.g., atezolizumab). The treatment regimen may be administered with chemotherapy or following a neoadjuvant chemotherapy regimen. Also provided are compositions (e.g., compositions comprising a PD-1 axis binding antagonist (e.g., atezolizumab) and/or an anti-TIGIT antagonist antibody (e.g., tiragolumab), including pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating cancer, e.g., gastric cancer (e.g., a GC or a GEJC (e.g., inoperable, locally advanced, metastatic, or advanced GC or GEJC)) or rectal cancer (e.g., LARC) in a subject. |
---|---|
Bibliography: | Application Number: US202418423520 |